86.0 A
Orforglipron
Also known as: LY3502970
Strong Clinical Evidence Research Chemical
Research Evidence 92.0/100
Safety Profile 80.0/100
46 Clinical Trials
PHASE3: 23 PHASE2: 2 PHASE1: 21
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) PHASE3 RECRUITING Eli Lilly and Company
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease PHASE3 RECRUITING Eli Lilly and Company
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight PHASE3 RECRUITING Eli Lilly and Company
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee PHASE3 RECRUITING Eli Lilly and Company
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes PHASE3 RECRUITING Eli Lilly and Company
Showing 5 of 46 trials.
16 Research Papers
- One small molecule for man, one giant leap for mankind with obesity. Med unknown
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet Human
- Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS. Expert Rev Endocrinol Metab unknown
- Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens. Acta Diabetol Review
- Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes. Cardiol Rev unknown
Showing 5 of 16 papers by citation count.
FDA Data
Not FDA-Approved
Orforglipron has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
Frequently Asked Questions
Is Orforglipron FDA approved?
No, Orforglipron has not been approved by the FDA for human therapeutic use. It is sold as a research chemical.
How many clinical trials has Orforglipron been studied in?
Orforglipron has been studied in 46 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Orforglipron?
Orforglipron has a CheckPeptides trust score of 86.0/100 (grade: A). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- Oral non-peptide GLP-1 receptor agonist
- Molecular Weight
- 883.0 Da
- PubChem
- CID 137319706 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 92.0/100
Safety Profile 80.0/100
Evidence Summary
- Clinical Trials
- 46
- Research Papers
- 16
- Trust Score
- 86.0/100
- Grade
- A